InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-1.5%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by MCLAUGHLIN KEVIN F, Director. Officer active across 3 companies, notably Vericel Corp. In total, 18 disclosures have been published. Activity tracked since 23 September 2021. The latest transaction was disclosed on 13 May 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
3,500 shares@ US$2.630.0005% mcap33.7% of flowCommon StockSEC:0001140361-26-021656
3,500 shares@ US$2.630.0005% mcap16.8% of flowCommon StockSEC:0001140361-26-021656:0
7,000 shares@ US$2.630.0009% mcap33.2% of flowCommon StockSEC:0001140361-26-005417:0
7,000 shares@ US$2.6333.2% of flowCommon StockSEC:0001140361-26-005417
7,000 shares@ US$2.7613.4% of flowCommon StockSEC:0001140361-25-018156:0
3,200 sharesCommon StockSEC:0001140361-25-017117:0
6,000 shares@ US$3.7417.0% of flowCommon StockSEC:0001140361-25-004765:0
7,000 shares@ US$3.7419.4% of flowCommon StockSEC:0001140361-24-047070:0
5,000 shares@ US$3.7413.5% of flowCommon StockSEC:0001140361-24-036617:0
3,200 sharesCommon StockSEC:0001140361-24-024330:0
5,000 sharesCommon StockSEC:0000899243-23-019494:0
5,000 shares0Common StockSEC:0000950170-23-027990:0
2,600 sharesCommon StockSEC:0001140361-23-021500:0
2,600 sharesCommon StockSEC:0001593968-22-000890:0
10,681 sharesCommon StockSEC:0001104659-21-142266:0
10,681 sharesCommon StockSEC:0001104659-21-142266
2,500 shares@ US$30.1750.0% of flowCommon StockSEC:0001179110-21-008935:0
2,500 shares@ US$30.17100.0% of flowCommon StockSEC:0001179110-21-008935
18 of 18 declarations
About MCLAUGHLIN KEVIN F
Kevin F. McLaughlin is a Director and Senior Vice President, Chief Financial Officer, and Treasurer at Vericel Corp and Acceleron Pharma Inc. He contributes to the governance of the companies and financial management. McLaughlin brings valuable expertise in the biopharmaceutical sector.
